A new report suggests that millions of U.S. adults are unaware they may have undiagnosed cardiovascular risk factors that ...

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).

Jay N. Yepuri, MD, MS, FACG, is a board-certified gastroenterologist and member of the Digestive Health Associates of Texas Board of Directors and Executive Committee. A liver function test checks how ...

Because of this, kidney problems often fail to show early symptoms, and many people remain unaware until serious damage occurs. A crucial factor to understand is that kidney health differs between ...

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the ...

Researchers discover a gut-brain-heart axis where the bacterial metabolite IAA regulates hypocretin neurons to control heart stiffness and blood pressure.

Guideline-directed medical therapy and dose titration are essential to improving outcomes in heart failure with reduced or mildly reduced ejection fraction.According to the CDC, 6.7 million U.S.

Skipping water in the morning can gradually increase blood pressure over time. Before grabbing a cup of coffee, have a glass of water. For healthy blood pressure, prioritize sleep, daily movement and ...

These foods provide a healthy dose of potassium per serving and can help you meet your recommended daily intake naturally.

Men and women experience kidney disease differently due to hormones, biology and lifestyle. Women develop it more often but slower, while men progress faster. Early screening, timely treatment and ...

Introduction Maintaining normal fluid status is critical to health and well-being. Older people are vulnerable to abnormal fluid status and associated complications, morbidity and mortality. Care home ...

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026Budoprutug clinical trials ongoing in pMN, ...